A detailed history of Loomis Sayles & CO L P transactions in Abb Vie Inc. stock. As of the latest transaction made, Loomis Sayles & CO L P holds 78,590 shares of ABBV stock, worth $13.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
78,590
Previous 214,907 63.43%
Holding current value
$13.8 Million
Previous $36.9 Million 57.9%
% of portfolio
0.02%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$163.84 - $199.33 $22.3 Million - $27.2 Million
-136,317 Reduced 63.43%
78,590 $15.5 Million
Q2 2024

Aug 13, 2024

BUY
$154.79 - $180.76 $6.94 Million - $8.1 Million
44,821 Added 26.35%
214,907 $36.9 Million
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $17 Million - $19.4 Million
-106,412 Reduced 38.49%
170,086 $31 Million
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $2.65 Million - $2.99 Million
19,285 Added 7.5%
276,498 $42.8 Million
Q3 2023

Nov 09, 2023

BUY
$133.59 - $154.65 $28.3 Million - $32.7 Million
211,591 Added 463.79%
257,213 $38.3 Million
Q2 2023

Aug 11, 2023

SELL
$132.51 - $164.9 $1.13 Million - $1.41 Million
-8,521 Reduced 15.74%
45,622 $6.15 Million
Q1 2023

May 11, 2023

SELL
$144.61 - $166.54 $155,455 - $179,030
-1,075 Reduced 1.95%
54,143 $8.63 Million
Q4 2022

Feb 10, 2023

SELL
$138.31 - $165.87 $234,020 - $280,652
-1,692 Reduced 2.97%
55,218 $8.92 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $18.1 Million - $20.7 Million
-134,496 Reduced 70.27%
56,910 $7.64 Million
Q2 2022

Aug 05, 2022

SELL
$137.62 - $174.96 $15.2 Million - $19.4 Million
-110,700 Reduced 36.64%
191,406 $29.3 Million
Q1 2022

May 13, 2022

SELL
$131.98 - $163.75 $5.18 Million - $6.42 Million
-39,231 Reduced 11.49%
302,106 $49 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $36.6 Million - $46.3 Million
340,755 Added 58548.97%
341,337 $46.2 Million
Q2 2021

Aug 13, 2021

BUY
$105.21 - $117.21 $12,940 - $14,416
123 Added 26.8%
582 $66,000
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $9,104 - $10,023
89 Added 24.05%
459 $50,000
Q4 2020

Feb 12, 2021

SELL
$80.49 - $108.67 $879,916 - $1.19 Million
-10,932 Reduced 96.73%
370 $40,000
Q3 2020

Nov 12, 2020

SELL
$85.91 - $100.83 $22,078 - $25,913
-257 Reduced 2.22%
11,302 $989,000
Q2 2020

Aug 14, 2020

SELL
$73.37 - $98.18 $179,463 - $240,148
-2,446 Reduced 17.47%
11,559 $1.14 Million
Q1 2020

May 15, 2020

SELL
$64.5 - $97.79 $862,429 - $1.31 Million
-13,371 Reduced 48.84%
14,005 $1.07 Million
Q4 2019

Feb 14, 2020

SELL
$72.13 - $90.25 $2.12 Million - $2.65 Million
-29,328 Reduced 51.72%
27,376 $2.42 Million
Q3 2019

Nov 13, 2019

SELL
$62.98 - $75.72 $141,201 - $169,764
-2,242 Reduced 3.8%
56,704 $4.29 Million
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $374,424 - $478,602
-5,699 Reduced 8.82%
58,946 $4.29 Million
Q1 2019

May 15, 2019

BUY
$77.14 - $90.79 $778,805 - $916,615
10,096 Added 18.51%
64,645 $5.21 Million
Q4 2018

Feb 14, 2019

BUY
$77.85 - $96.01 $3.92 Million - $4.84 Million
50,378 Added 1207.82%
54,549 $5.03 Million
Q3 2018

Nov 13, 2018

SELL
$88.91 - $98.84 $287,534 - $319,648
-3,234 Reduced 43.67%
4,171 $394,000
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $89 - $106
1 Added 0.01%
7,405 $686,000
Q1 2018

May 11, 2018

SELL
$92.01 - $123.21 $338,964 - $453,905
-3,684 Reduced 33.23%
7,404 $701,000
Q4 2017

Feb 14, 2018

SELL
$89.56 - $98.21 $458,726 - $503,031
-5,122 Reduced 31.6%
11,088 $1.07 Million
Q3 2017

Nov 14, 2017

SELL
$69.85 - $89.22 $452,139 - $577,521
-6,473 Reduced 28.54%
16,210 $1.44 Million
Q2 2017

Aug 14, 2017

BUY
N/A
22,683
22,683 $1.65 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.